250,000 patients treated.[1]* Millions of special moments.
Over a decade ago, IMBRUVICA® (ibrutinib) revolutionised the treatment landscape for chronic lymphocytic leukaemia (CLL).[2] Since then, we’ve been dedicated in our search to provide a long and active life for people with B cell malignancies.[1][2][3]*
We are grateful for all of the positive experiences our patients have had while using IMBRUVICA®. Reaching this milestone of 250,000 people treated worldwide[1]* means so much more than numbers. For us, it is a chance to celebrate the millions of special moments our patients and their loved ones can enjoy together.
*Patients treated in mantle cell lymphoma, Waldenström's macroglobulinaemia and chronic lymphocytic leukaemia indications.
IMBRUVICA® as a single agent is approved for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL). IMBRUVICA® as a single agent or in combination with rituximab or obinutuzumab is approved for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL). IMBRUVICA® as a single agent or in combination with bendamustine and rituximab (BR) is approved for the treatment of adult patients with CLL who have received at least one prior therapy. IMBRUVICA® as a single agent is approved for the treatment of adult patients with Waldenström’s macroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. IMBRUVICA® in combination with rituximab is approved for the treatment of adult patients with WM.[3]
